I believe we will soon get a significant re rating as the market...

I believe we will soon get a significant re rating as the market comes to understand the impact of our Pandas Pans and ASD results.
The benefits of our product having so little side effects and significantly improving the lives of these children, will soon can to the forefront of the market.


Daybue which has just been launched in the USA, which made Neu a multi billion $ company.

Facts:
Plus in their latest quarterly they state that after 6 months of treatment around 24% of participants ceased taking this medication, isn't this a high churn rate?

Our results for Pandas Pans and ASD, I believe are showing better percentage results, using the gold standard makers of CGI and Vineland.

Our significant advantage is we have limited or no side effects and in The words of Professor Dale :

"I have observed quite profound improvements in a number of my patients with NTI164, making it the first trial of its kind with a broad-spectrum cannabinoid therapy showing initial clinical utility like this with excellent safety.
In addition, we await further evidence of genomic molecular changes from baseline measures and after 12 weeks of treatment to correlate this meaningful clinical response we have seen with biological evidence of effect.
This would be a major step-forward for PANDAS/PANS patients and assist in identifying relevant biomarkers of the disease."

Note " we await further evidence"

Hopefully there is further news coming on this "major step-forward"

Also see our ASD results and comments by Professor Fahey.

https://announcements.asx.com.au/asxpdf/20230317/pdf/45ms94q65537pg.pdf.

Our re rate will come.

We just have received our HREC approval for both a Rett and Cerebral Palsy trials--

I believe, the new, better and improved Neuron is coming !!!!

Just cheap -- real cheap